Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 1, 2013, Pages 87-93

  Müller, Patrick ^a   Kazakov, Andrey ^a   Semenov, Alexander ^a   Jagoda, Philippe ^a   Friedrich, Erik B ^a   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

ACE inhibition; angiotensin receptor blockade; cardiac pressure overload; endothelial progenitor cells

Indexed keywords

KI 67 ANTIGEN; PLACEBO; RAMIPRIL; TELMISARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; AORTA CONSTRICTION; ARTICLE; BONE LENGTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENDOTHELIAL PROGENITOR CELL; HEART HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CAPILLARY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART WEIGHT; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TIBIA; TISSUE STRUCTURE; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOMEGALY; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; FIBROSIS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; RAMIPRIL; STEM CELLS;

EID: 84871556531     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411434773     Document Type: Article

References (25)

1. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982 ; 4 (6). 966-972
2. Borland JA, Kelsall C, Yacoub MH, Chester AH. Expression, localisation and function of ACE and chymase in normal and atherosclerotic human coronary arteries. Vascul Pharmacol. 2005 ; 42: 99-108
3. Yang HY, Erdös EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther. 1971 ; 177 (1). 291-300
4. Werner C, Baumhäkel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008 ; 97 (7). 418-431
5. Werner N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003 ; 93 (2). e17 - e24
6. Müller P, Kazakov A, Semenov A, Böhm M, Laufs U. Pressure-induced cardiac overload induces upregulation of endothelial and myocardial progenitor cells. Cardiovasc Res. 2008 ; 77 (1). 151-159
7. Müller P, Kazakov A, Jagoda P, Semenov A, Böhm M, Laufs U. ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. Cardiovasc Res. 2009 ; 83 (1). 106-114
8. Porto I, Di Vito L, De Maria GL, et al. Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome. Am J Cardiol. 2009 ; 103 (11). 1500-1505
9. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 (15). 1547-1559
10. Yusuf S, Teo K, Anderson C, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 ; 372 (9644). 1174-1183
11. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004 ; 109 (2). 220-226
12. Kawai M, Hongo K, Komukai K, et al. Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. Hypertens Res. 2009 ; 32 (7). 604-610
13. Susic D, Varagic J, Fröhlich ED. Cardiovascular effects on inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess. Am J Physiol Heart Circ Physiol. 2010 ; 298 (4). H1177 - H1181
14. Grimm D, Kromer EP, Böcker W, et al. Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. J Hypertens. 1998 ; 16 (9). 1345-1355
15. Seeland U, Kouchi I, Zolk O, Itter G, Linz W, Böhm M. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol. 2002 ; 34 (2). 151-163
16. Seeland U, Schäffer A, Selejan S, et al. Effects of AT1-and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice. Eur J Clin Invest. 2009 ; 39 (10). 851-859
17. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005 ; 115 (8). 2108-2118
18. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation. 1987 ; 75 (1 pt 2). I19 - I25
19. Ziada AM, Hassan MO, Tahlilkar KI, Inuwa IM. Long-term exercise training and angiotensin-converting enzyme inhibition differentially enhance myocardial capillarization in the spontaneously hypertensive rat. J Hypertens. 2005 ; 23 (6). 1233-1240
20. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol. 2005 ; 25 (1). 65-70
21. Li JM, Mogi M, Iwanami J, et al. Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density. Stroke. 2008 ; 39 (7). 2029-2036
22. Yoshiji H, Kuriyama S, Noguchi R, et al. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep. 2006 ; 15 (1). 155-159
23. Rakusan K, Chvojkova Z, Oliviero P, et al. ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats. Am J Physiol Heart Circ Physiol. 2007 ; 292 (3). H1237 - H1244
24. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg. 2007 ; 204 (5). 996-1005
25. Cowan BR, Young AA, Anderson C, et al. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clin Res Cardiol. 2009 ; 98 (7). 421-433